Compounded Semaglutide: What You Need to Know Before You Start

Semaglutide has reshaped how physicians and patients approach metabolic health and sustainable weight loss. But as demand for GLP-1 therapy has grown, so has interest in compounded versions. Here is what the science, the FDA, and your physician actually want you to understand.

Key Takeaways

• Semaglutide is one of the most studied FDA approved GLP-1 receptor agonists available, with robust clinical trial data supporting meaningful weight loss outcomes.
• Compounded semaglutide is not FDA approved, meaning it bypasses the safety, effectiveness, and quality review process applied to FDA approved drugs.
• The FDA declared the semaglutide shortage resolved in February 2025, which significantly narrowed the legal pathway for compounding pharmacies to produce compounded versions.
• Dosing errors with compounded drugs have led to reported hospitalizations, making physician oversight critical for anyone using or transitioning off compounded semaglutide.
• Physician-guided protocols that prioritize safety, quality sourcing, and individualized dosing remain the gold standard for sustainable weight management.

What Is Semaglutide and Why Does It Matter for Weight Loss?

Semaglutide belongs to a class of medications called GLP-1 receptor agonists. These compounds mimic glucagon-like peptide 1, a naturally occurring hormone that regulates appetite, insulin release, and gastric emptying.

In plain terms: you feel full faster, you think about food less, and your body processes glucose more efficiently. When combined with a reduced calorie diet and increased physical activity, these effects can translate into clinically significant weight loss outcomes.

The STEP clinical trials, a landmark series of randomized controlled trials, evaluated once-weekly semaglutide in adults with obesity or overweight. Participants across multiple STEP trials achieved average body weight reductions ranging from approximately 15 to 17 percent over 68 weeks compared to placebo.¹

More recently, the STEP UP trial presented data showing that a higher investigational dose of semaglutide produced a mean weight loss of approximately 21 percent over 72 weeks in adults without diabetes, with over 90 percent of participants achieving at least 5 percent weight loss.²

These results have made semaglutide one of the most studied weight loss drugs in modern medicine.

How GLP-1 Receptor Agonists Work

GLP-1 receptor agonists work by binding to receptors found in the brain, gut, and pancreas. When activated, these receptors slow gastric emptying, stimulate insulin secretion in a glucose-dependent manner, and reduce appetite signaling.

The practical outcome is that many patients report eating smaller portions naturally, feeling satisfied earlier in meals, and experiencing fewer cravings throughout the day.

GLP-1 drugs do not require willpower to override. They change the underlying hormonal signals that drive hunger and satiety. This is why the clinical trial results are so consistently strong compared to diet and exercise interventions alone.

Understanding how GLP-1 receptor agonists work is important context for evaluating both FDA approved medications and compounded alternatives.

FDA Approved Semaglutide: The Clinical Standard

FDA approved semaglutide products have undergone rigorous review for safety, effectiveness, and manufacturing quality before reaching patients.

The FDA approved drug review process evaluates preclinical data, Phase I through Phase III clinical trials, manufacturing standards, labeling accuracy, and post-market surveillance. This process is not a formality. It exists to protect patients from unsafe or ineffective compounds.

Oral semaglutide has also demonstrated meaningful results. The Phase 3 PIONEER-1 clinical trial evaluated once-daily oral semaglutide across multiple dosing groups over 26 weeks, showing statistically significant improvements in blood sugar control at all tested doses, along with weight loss outcomes at the 14 mg dose compared to placebo.³

A broader review of oral GLP-1 therapies published in 2025 highlighted that the OASIS-4 trial of oral semaglutide 25 mg in 307 adults over 64 weeks showed a mean weight loss of 13.6 percent, with over 63 percent of participants losing 10 percent or more of body weight.⁴

The availability of both injectable and oral FDA approved semaglutide options represents a meaningful expansion of access for patients who prefer non-injectable formats.

What Is Compounded Semaglutide?

Compounded semaglutide refers to versions of the compound prepared by compounding pharmacies outside of the standard FDA approved drug manufacturing pathway.

Compounded drugs are not FDA approved. They do not undergo the FDA's review for safety, effectiveness, or quality before being marketed to patients.⁵ This is a critical distinction that every person considering a GLP-1 protocol should understand.

Compounding pharmacies serve a legitimate medical purpose. They can prepare customized medications for patients with documented needs that FDA approved medications cannot meet, such as specific allergies or unique dosing requirements.

Compounded versions of semaglutide became widely available during a period when FDA approved semaglutide products were listed on the FDA's official drug shortage list, beginning in 2022. During a declared shortage, federal law permits compounding pharmacies to produce compounded drugs that would otherwise be prohibited as copies of FDA approved drugs.

However, that shortage was declared resolved by the FDA in February 2025.⁶ As of that point, the legal basis for most compounding of semaglutide under the shortage exemption ended.

The FDA's Concerns About Compounded GLP-1 Drugs

The FDA has been direct about its concerns with compounded semaglutide and compounded GLP 1 medications broadly.

The agency has received reports of adverse events linked to compounded injectable semaglutide products, including nausea, vomiting, diarrhea, abdominal pain, and constipation, with some patients requiring medical attention. As of late February 2025, the FDA had received more than 455 reports of adverse events with compounded semaglutide.⁷

Dosing errors represent a particularly serious concern. Reports of dosing errors with compounded drugs have led to hospitalizations, often due to confusion around units of measurement, variations in concentration across different compounders, or patients self-administering incorrect volumes.⁷

The FDA has also received reports of compounded semaglutide products arriving warm or without adequate refrigeration, which can compromise the compound's stability and safety.

Some compounded versions have also been found to contain salt forms of semaglutide (such as sodium or acetate), rather than the active base compound used in FDA approved products. These salt forms have not been shown to have the same pharmacological profile as the FDA approved active ingredient.

Compounded Versions and Legal Status After the Shortage

Federal law generally prohibits compounding pharmacies from producing compounded drugs that are essentially copies of a commercially available FDA approved drug.

The shortage exception allowed wide production of compounded semaglutide between 2022 and early 2025. Since the shortage resolution, 503A compounding pharmacies lost the ability to rely on that exception after April 22, 2025, and 503B outsourcing facilities after May 22, 2025.⁶

Outside of specific documented patient needs such as allergies or intolerances to inactive ingredients in FDA approved products, producing or dispensing compounded semaglutide is no longer permitted under standard federal law. Health care providers and patients relying on compounded versions were advised to transition to FDA approved semaglutide products.

The FDA has stated that compounded drugs should only be used when a patient has a medical need that cannot be fulfilled by an FDA approved drug.

Safety Risks of Compounded Semaglutide

Compounded semaglutide carries safety risks that are distinct from FDA approved medications.

Because compounded medications from state licensed pharmacy operations are not required to submit adverse event reports to the FDA under federal law, the true scope of reported events is likely underreported.⁵

Risks associated with compounded drugs include potential for incorrect dosing, contamination, harmful ingredients from unverified active pharmaceutical ingredients, and inconsistent potency between batches.

Serious health risks associated with semaglutide at any dose include pancreatitis, kidney problems, and potential increased risk of thyroid C-cell tumors based on animal data. These risks require physician oversight regardless of the source of the medication.

Allergic reactions have been reported with semaglutide. Health care professionals should be consulted before starting any GLP-1 protocol, and health care providers should be notified of any adverse events promptly.

Anyone receiving compounded drugs through channels that do not involve licensed health care providers, documented physician oversight, and legitimate specific compounding pharmacies operating under USP standards should exercise significant caution.

The Case for Microdosing and Personalized GLP-1 Protocols

One of the more compelling emerging areas in GLP-1 medicine is the concept of personalized, lower-dose titration protocols, often called microdosing, as a strategy for improving tolerability, adherence, and long-term sustainability.

The standard clinical dosing ladder for semaglutide begins at low weekly doses and escalates gradually. Many patients experience gastrointestinal side effects as doses increase, and a meaningful percentage of people who begin standard-dose GLP-1 medications discontinue within the first year.⁸

The rationale for lower, gradual dosing is not to avoid therapeutic benefit but to build toward it while reducing the severity of side effects, improving patient adherence, and supporting long-term weight management. This approach prioritizes sustainable wellness outcomes over rapid, high-dose intervention.

Physicians at platforms like Whoosh can work with patients to design individualized protocols that match GLP-1 dosing to each person's response, goals, and tolerance, rather than applying a one-size-fits-all standard dose schedule.

What to Ask Your Physician Before Starting Any GLP-1 Protocol

Before starting any semaglutide-related protocol, whether FDA approved or otherwise, a few questions matter.

Is the source of the medication FDA approved or compounded? This determines what quality and safety review it has undergone.

Does the prescribing platform involve ongoing physician oversight, or is it a one-time prescription with no follow-up? Semaglutide protocols require ongoing care, including monitoring for adverse events and dosing adjustments.

Is the dosing protocol individualized? Standard weight loss protocols may not be appropriate for every person, and your intended dose should be calibrated to your health history, weight management goals, and tolerance.

Are there safer delivery options available? Oral semaglutide formulations are FDA approved and may be appropriate for individuals who prefer non-injectable protocols.

Health care professionals who take the time to answer these questions clearly are the right partners for any GLP-1 weight loss protocol.

Whoosh and Physician-Guided Weight Loss

Whoosh is a premium physician-guided telehealth wellness platform designed for health-conscious adults who want modern, science-backed approaches to metabolic health, weight management, and performance.

Rather than operating as a transactional prescription service, Whoosh prioritizes ongoing physician oversight, quality sourcing, and education-first wellness protocols. The platform offers both injectable and oral delivery formats where scientifically appropriate, reducing friction for people who prefer alternatives to injections.

Whoosh physicians work with patients to develop personalized protocols grounded in clinical evidence, including for GLP-1 based weight loss support. Every protocol involves ongoing care, clear dosing instructions, and physician availability throughout the process.

If you are ready to explore a physician-guided approach to weight loss and metabolic optimization, contact Whoosh today.

Conclusion

Semaglutide is one of the most rigorously studied weight loss drugs in modern medicine, with robust clinical trial evidence supporting its effectiveness as a GLP-1 receptor agonist. FDA approved products offer the quality, safety, and consistency that compounded versions cannot provide.

Compounded semaglutide served a purpose during a period of genuine shortage, but the legal and regulatory framework for most compounded drugs in this category has shifted substantially. Patients and physicians should understand both the safety risks and the current legal status before making any protocol decisions.

The best weight loss outcomes come from physician-guided, individually tailored protocols that combine effective medications with sustainable lifestyle support, not from unregulated shortcuts.

About Whoosh

Whoosh is a premium physician-guided telehealth wellness platform focused on helping health-conscious adults optimize performance, longevity, recovery, and metabolic health through modern prescription wellness protocols. Built for people who already invest in their health, Whoosh combines a seamless online experience with ongoing physician oversight, trusted pharmaceutical partnerships, and science-backed wellness education. The experience is designed to feel approachable, modern, and discreet. Patients complete a streamlined online intake, connect with licensed physicians remotely, and receive personalized physician-guided protocols delivered directly to their door, all through a compliant, fully remote process.

Frequently Asked Questions

What is compounded semaglutide?

Compounded semaglutide is a version of the GLP-1 receptor agonist semaglutide prepared by compounding pharmacies rather than through an FDA approved drug manufacturer. It is not FDA approved and does not undergo the same safety and quality review as FDA approved medications.

Is compounded semaglutide legal?

Outside of narrow exceptions such as documented patient allergies, compounded semaglutide is generally no longer legally permissible following the FDA's resolution of the semaglutide shortage in February 2025. Patients should consult their healthcare provider about transitioning to FDA approved options.

What are the risks of compounded semaglutide?

Safety risks include dosing errors, contamination, inconsistent potency, and potential harmful ingredients. The FDA has received hundreds of adverse event reports linked to compounded drugs in this category, including hospitalizations.

How does physician-guided semaglutide support weight loss?

FDA approved semaglutide works by activating GLP-1 receptor agonists that reduce appetite and slow gastric emptying. When paired with a reduced calorie diet and physician oversight, clinical trials have demonstrated average weight loss of 15 percent or more over 68 weeks.

References

1. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15386
   
2. https://www.appliedclinicaltrialsonline.com/view/wegovy-weight-loss-obesity-diabetes
   
3. https://diabetesjournals.org/care/article-abstract/42/9/1724/36289/PIONEER-1-Randomized-Clinical-Trial-of-the?redirectedFrom=fulltext
   
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12498447/
   
5. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
   
6. https://www.mwe.com/insights/semaglutide-shortage-resolved/
   
7. https://www.harrisbeachmurtha.com/insights/glp-1-weight-loss-drugs-off-shortage-list-deadlines-to-stop-compounding/‍
8. https://www.goodrx.com/conditions/weight-loss/microdosing-glp-1